Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (71)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kennedy, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kennedy, A. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1985 Oxford University Press

other

The conditions for the modification of radiation transformation in vitro by a tumor promoter and protease inhibitors

Ann R. Kennedy

Department of Cancer Biology, Harvard School of Public Health 665 Huntington Avenue, Boston MA 02115, USA

These experiments were designed to define the conditions necessary for the modification of radiation-induced transformation in C3H/10T1/2 cells by TPA and protease inhibitors. The results show that: (i) the lowest effective dose of various protease inhibitors to suppress transformation in vitro varies over several orders of magnitude; on a molar basis, the inhibitors of chymotrypsin appear to be the most effective protease inhibitors at suppression of radiation-induced transformation in vitro, (ii) the protease inhibitors antipain and the Bowman-Birk (soybean) protease inhibitor have no effect on radiation transformation when present only during irradiation, (iii) the protease inhibitor antipain can suppress radiation transformation in vitro when applied to proliferating ‘initiated’ cells as late as 10 days and 13 cell divisions post-irradiation, and (iv) TPA treatment following a 10-day protease inhibitor (antipain) exposure of X-irradiated ‘initiated’ cells does not lead to promotion in vitro. These results suggest that protease inhibitor treatment of the initiated cells has irreversibly reverted cells to their original or ‘uninitiated’ condition which existed before irradiation.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CarcinogenesisHome page
Y.-W. Chen, S.-C. Huang, S.-Y. Lin-Shiau, and J.-K. Lin
Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1
Carcinogenesis, July 1, 2005; 26(7): 1296 - 1306.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
W. B. Armstrong, A. R. Kennedy, X. S. Wan, J. Atiba, C. E. McLaren, and F. L. Meyskens Jr.
Single-Dose Administration of Bowman-Birk Inhibitor Concentrate in Patients with Oral Leukoplakia
Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 43 - 47.
[Abstract] [Full Text]

Home page
 Toxicol PatholHome page
K. Enomoto, A. Kaneko, M. Oyamada, Y. Oyamada, K. Dempo, and M. Mori
Induction of a Novel Ca2+-Dependent Serine Protease in Rat Liver Treated with Various Promoters of Liver Carcinogenesis
Toxicol Pathol, January 1, 1987; 15(1): 73 - 77.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.